At present, high PD-L1 expression, microsatellite instable-high (MSI-H)/mismatch repair deficient (dMMR) phenotype, and tumor mutation burden-high status (TMB-H) have been proposed as a predictive biomarker to predict response to PD-1 inhibitors in many cancers (93). The gene discussed is CD274; the disease is cancer.